Related Experiment Video

Updated: Feb 4, 2026

Single-Cell Multiplexed Fluorescence Imaging to Visualize Viral Nucleic Acids and Proteins and Monitor HIV, HTLV, HBV, HCV, Zika Virus, and Influenza Infection
07:24

Single-Cell Multiplexed Fluorescence Imaging to Visualize Viral Nucleic Acids and Proteins and Monitor HIV, HTLV, HBV, HCV, Zika Virus, and Influenza Infection

Published on: October 29, 2020

3.2K

HBV-HCV Coinfection: Viral Interactions, Management, and Viral Reactivation

Marianna G Mavilia1, George Y Wu1

  • 1Department of Medicine, Division of Gastroenterology-Hepatology, University of Connecticut Health Center, Farmington, CT, USA.

Journal of Clinical and Translational Hepatology
|October 2, 2018
PubMed

Insights

Hepatitis B virus (HBV) and hepatitis C virus (HCV) coinfection accelerates liver disease progression and hepatocellular carcinoma risk. Treatment strategies require careful consideration to prevent HBV reactivation, as no definitive guidelines exist.

Area of Science:

  • Hepatology
  • Virology
  • Clinical Medicine

Background:

  • Hepatitis B virus (HBV) and hepatitis C virus (HCV) coinfection affects 1-15% worldwide.
  • Coinfection typically leads to faster disease progression and higher rates of hepatocellular carcinoma compared to monoinfection.
  • HCV replication dominates over HBV in coinfected individuals.

Purpose of the Study:

  • To review and evaluate the efficacy of direct-acting antivirals and interferon-based therapies for HBV-HCV coinfection.
  • To assess the rates of HBV reactivation associated with different treatment regimens.
  • To highlight the importance of screening and prevention strategies.

Main Methods:

  • Systematic review of clinical studies on antiviral therapies for HBV-HCV coinfection.
  • Appraisal of studies focusing on direct-acting antivirals and interferon-based treatments.
  • Analysis of reported efficacy and HBV reactivation rates.

Main Results:

  • Interferon-based and direct-acting antiviral therapies show variable efficacy in treating HBV-HCV coinfection.
  • Treatment of HCV without concurrent HBV suppression increases the risk of HBV reactivation.
  • No established treatment guidelines currently exist for HBV-HCV coinfection.

Conclusions:

  • Careful management is crucial for HBV-HCV coinfected patients to prevent severe HBV reactivation.
  • Screening and prevention of coinfection are vital public health measures.
  • Further research is needed to establish optimal treatment guidelines.

Keywords:
CoinfectionHepatitis B virusHepatitis C virusViral reactivation

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.4K
Purification of Viral DNA for the Identification of Associated Viral and Cellular Proteins08:26

Purification of Viral DNA for the Identification of Associated Viral and Cellular Proteins

Published on: August 31, 2017

14.2K

Related Concept Videos

Viral Recombination00:57

Viral Recombination

Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
25.2K
Viral Structure00:56

Viral Structure

Viruses are extraordinarily diverse in shape and size, but they all have several structural features in common. All viruses have a core that contains a DNA- or RNA-based genome. The core is surrounded by a protective coat of proteins called the capsid. The capsid is composed of subunits called capsomeres. The capsid and genome-containing core are together known as the nucleocapsid.
74.6K
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
251
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.9K
Size and Structure of Viral Genomes01:26

Size and Structure of Viral Genomes

Viral genomes exhibit remarkable diversity in size, structure, and composition, influencing their replication strategies and interactions with host cells. These genomes consist of either DNA or RNA and may be linear or circular. Additionally, they can be single-stranded or double-stranded, with each configuration affecting how the virus propagates within a host. RNA viruses, for instance, generally have smaller genomes than DNA viruses, a factor that contributes to their high mutation rates and...
794
Viral Replication: Lytic Cycle01:20

Viral Replication: Lytic Cycle

Bacteriophages, or phages, are viruses that specifically infect bacteria. Among them, T-even bacteriophages, such as T4, exhibit a well-characterized lytic replication cycle in Escherichia coli (E. coli). This process ensures the rapid proliferation of the virus while ultimately leading to the destruction of the bacterial host.Attachment and DNA InjectionThe infection process begins with the recognition and binding of the T4 phage to the E. coli cell surface. Tail fibers of the phage...
1.6K